In the clinical setting, it is important not to exclude cystic fibrosis as a diagnosis based on race.⁵ Focusing health care on smaller subpopulations is difficult. It can take additional time and resources to properly diagnosis and treat these populations because they may not fit the standard procedures, but this needs to be addressed. Data shows that minority populations with cystic fibrosis suffer a greater burden from their disease and receive lower-quality healthcare.⁹ These populations are sicker, and they need more timely help.
It is important to try to reach these minorities because it may help understand why cystic fibrosis affects these populations more severely compared to the Caucasian population. As with all medical treatments and therapies, one therapy does not affect everyone exactly the same, so with more differing representation more breakthroughs might be found to help all those with cystic fibrosis. By excluding or ignoring minorities, intentionally of not, there is a potential for losing important information about determinants of drug responses, factors contributing to clinical manifestations of cystic fibrosis and possible health disparities for minorities.³